The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment ...

The U.S. Food and Drug Administration's mass layoffs included senior negotiators in talks with the pharmaceutical industry ...

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...

Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration (FDA) orphan drug designation (ODD) to treat two rare conditions: ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for Regeneron, one with partner Sanofi.

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...